Boston—Treatment options for patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) have increased dramatically, with seven new therapies approved between October 2017 and April 2021, and several others in the pipeline.
“We’ve seen really exciting changes in the options that are available for these patients,” said Soniya Chandrasekhara, PharmD, a clinical pharmacist in hematology/oncology/bone marrow transplant at Stanford Health Care, in Palo Alto,